Navigation Links
Molecular Profiles Joins Leading Consortium To Drive Paediatric Formulation Development
Date:12/19/2013

NOTTINGHAM, England, Dec. 19, 2013 /PRNewswire/ --A collaborative pharmaceutical project focused on improving the pathway for developing paediatric formulations has been given the go-ahead after successfully securing an innovation grant.

The UK-wide consortium, led by Astra Zeneca, received a £660k grant from the UK's innovation agency, the Technology Strategy Board, to help fund a £1million project aimed at accelerating paediatric formulation development through smart design and predictive science.

The consortium is comprised of pharmaceutical analytical development specialist Molecular Profiles along with Pfizer, Bristol Myers Squibb, GlaxoSmithKline and academic institutions including University College London, University of Bath, University of Birmingham, Aston University and the Academy of Pharmaceutical Sciences (a not-for-profit organisation).

Paediatric formulation development is more complex than the associated adult medicines. In addition to considering the differences in physiology and anatomy, paediatric formulations must offer flexible dosing and provide effective taste-masking.

This project will address the need to improve the speed, cost and quality of paediatric formulation development by drawing on the combined expertise of the consortium members. The goal is to deliver a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy.

Molecular Profiles' chief executive officer Nikin Patel said: "This collaborative project is an ambitious venture aimed at developing a strategic pathway to expedite the development of paediatric formulations, establishing the UK as a global leader in this area. Receipt of the Technology Strategy Board grant will enable us to move forward with this multi-partner project.

"To be involved with such credible consortium members from both la
'/>"/>

SOURCE Columbia Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
4. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
5. The 2012 US Molecular Diagnostics Market
6. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
7. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
8. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
9. Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare To Care."
10. IBA Molecular, Piramal Imaging Sign Agreement for New F-18 Amyloid Imaging Agent
11. New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... ... , MAPLE GROVE, Minn. , Jan. 27 ... Divigel ® (estradiol gel 0.1%), prescribed for the management of moderate-to-severe hot ... and compounded bioidentical hormones.(1) A review of the evidence was recently published in ...
... , , , , RALEIGH, N.C. , ... Research Organization, announces it has entered into a partnership agreement ... its exclusive partner IBPC, a non-profit oncology research network comprised ... treat an estimated 140,000 new incidences of cancer annually.  Under ...
Cached Medicine Technology:New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 2New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 3New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 4New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 5New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 6New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 7New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 8New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 9New Article: Non-Patch, Transdermal Estrogen Products Such as Divigel(R) Are Effective Hormone Therapy Alternatives to Oral Estrogen 10PRA International Formalizes Partnership with Oncopartners and IBPC 2PRA International Formalizes Partnership with Oncopartners and IBPC 3PRA International Formalizes Partnership with Oncopartners and IBPC 4PRA International Formalizes Partnership with Oncopartners and IBPC 5
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... Dar, Ethiopia, at the occasion of the Leishmaniasis ... 150 African and international leishmaniasis experts, results of ... efficacy monitoring plan, carried out by MSF, ... and Ethiopia, were presented to key decision makers ... of kala-azar with the combination of Sodium Stibogluconate ...
Breaking Medicine News(10 mins):Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2
... 2011.- The President of the BBVA Foundation, Francisco ... General Hospital Cancer Center (MGHCC), and Andrs de ... of Oncology (VHIO) in Barcelona, yesterday signed the ... Program. Also attending the event was the Foundation,s ...
... News) -- Women and younger men account for a large ... less likely than older men to receive preventive medications that ... evaluated more than 3,000 heart attack patients treated at the ... found that 70.3 percent of them had not been diagnosed ...
... the breast cancer drug tamoxifen in male breast cancer patients ... because of problems with side effects caused by the drug. ... in the cancer journal Annals of Oncology [1], ... their institution who had received tamoxifen for an average of ...
... Patients who rely on recombinant, protein-based drugs must ... week, or intravenous therapy. Researchers at Children,s Hospital ... from genetically engineered cells, could secrete the drug ... November 17 issue of the journal Blood ...
... Randy Dotinga HealthDay Reporter , TUESDAY, Nov. 15 ... doesn,t appear to improve the bone health of postmenopausal ... The treatment -- which involves standing on a motorized, vibrating ... promise in animals. But researchers, who hoped those results might ...
... be one of the topics of a conference at UC ... the UC Davis Center for Mind and Brain, Gallaudet University,s ... and the departments of psychology and linguistics at UC Davis. ... said David Corina, professor in the Department of Linguistics and ...
Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Visual language, cognition and deaf education topics of summit 2
0.2 mm, 90o angled tip. Flat smooth handle with polished finish....
Nucleus manipulator facilitates lens rotation during phacoemulsification....
Straight shaft with 0.2 mm hour glass shape tip. Round knurled handle with dull finish. Manufactured in titanium....
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Medicine Products: